Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.45 |
| ▸ | F11 | P03951 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979565 | 0.81 | LPL (0.57) | LPLLIPGF11TRPV1CA1 | |
| SCHEMBL13150992 | 0.76 | LPL (0.61) | LPLLIPGF11TRPV1CA1 | |
| SCHEMBL6356134 | 0.76 | TRPV1 (0.58) | LPLLIPGF11TRPV1CA1 | |
| SCHEMBL2946360 | 0.74 | ENPP2 (0.44) | LPLLIPGF11TRPV1CA1 | |
| SCHEMBL9514691 | 0.74 | CHRM2 (0.64) | CA1CA2MEN1KMT2ATDP1 | |
| SCHEMBL24274799 | 0.73 | MPO (0.36) | CA1CA2 | |
| SCHEMBL19272703 | 0.73 | LPL (0.46) | LPLLIPGF11TRPV1CA1 | |
| SCHEMBL27265652 | 0.73 | DPP7 (0.64) | KMT2A | |
| SCHEMBL2315417 | 0.73 | MEN1 (0.73) | MEN1KMT2ATDP1 | |
| SCHEMBL7651263 | 0.73 | LPL (0.61) | LPLLIPGF11TRPV1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292709-B1 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EIDGENOESS TECH HOCHSCHULE (CH) | 2012-01-18 | — | — | EP | disclosed |
| US-7291673-B2 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSICHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2007-11-06 | — | — | US | disclosed |
| US-20030220245-A1 | Conjugate addition reactions for the controlled delivery of pharmaceutical active compounds | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220245-A1 | Conjugate addition reactions for the controlled delivery of pharmaceutical active compounds | PAICS, C9, LIPA | LPL 758/4885LIPG 194/4885F11 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.